Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 7/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.58 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.58 |
| ▸ | TBXAS1 | P24557 | 9/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10672549 | 0.87 | TBXAS1 (0.73) | CYP19A1NPC1POLBTBXAS1 | |
| SCHEMBL16684296 | 0.86 | TBXAS1 (0.64) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL18180504 | 0.85 | CYP19A1 (0.64) | CYP19A1NPC1POLBCYP11B1CYP11B2 | |
| SCHEMBL20601870 | 0.84 | CYP19A1 (0.66) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL10674009 | 0.83 | CYP19A1 (0.60) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL12639833 | 0.83 | CYP19A1 (0.68) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL10998867 | 0.82 | CYP19A1 (0.62) | CYP19A1NPC1POLBCYP11B1CYP11B2 | |
| SCHEMBL22064348 | 0.82 | CYP19A1 (0.60) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL10674015 | 0.82 | CYP19A1 (0.59) | CYP19A1CYP11B1CYP11B2TBXAS1 | |
| SCHEMBL4701021 | 0.81 | CYP19A1 (0.70) | CYP19A1POLBCYP11B1CYP11B2TBXAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118005563-A | N-benzyl imidazole derivative and preparation method and application thereof | 中国药科大学 | 2024-05-10 | — | — | CN | disclosed |
| US-9708279-B2 | 2-acylaminothiazoles for the treatment of cancer | UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) | 2017-07-18 | — | — | US | disclosed |
| US-9708279-B2 | 2-acylaminothiazoles for the treatment of cancer | UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) | 2017-07-18 | — | — | US | disclosed |
| US-9708279-B2 | 2-acylaminothiazoles for the treatment of cancer | UNIVERSITÁ DEGLI STUDI DI MILANO—BICOCCA (IT) | 2017-07-18 | — | — | US | disclosed |
| EP-3016948-B1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2017-05-10 | — | — | EP | disclosed |
| EP-3016948-B1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITÀ DEGLI STUDI DI MILANO - BICOCCA (IT) | 2017-05-10 | — | — | EP | disclosed |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) | 2016-09-08 | — | — | US | disclosed |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) | 2016-09-08 | — | — | US | disclosed |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | UNIVERSITE' CLAUDE BERNARD LYON 1 (FR) | 2016-09-08 | — | — | US | disclosed |
| EP-3016948-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | Università Degli Studi Di Milano - Bicocca (IT) | 2016-05-11 | — | — | EP | disclosed |
| US-20110118325-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2011-05-19 | — | — | US | disclosed |
| EP-1187816-B1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LTD (GB) | 2006-12-20 | — | — | EP | disclosed |
| CN-1168721-C | 5-cyano-2-aminopyrimidine derivatives | О | 2004-09-29 | — | — | CN | disclosed |
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMTIED | 2004-09-16 | — | — | US | disclosed |
| US-6579983-B1 | Potent and selective inhibitors of receptor tyrosine kinases involved in angiogenesis, especially KDR kinase and/or FGFr kinase | CELLTECH R&D LIMITED (GB) | 2003-06-17 | — | — | US | disclosed |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | CELLTECH R&D LIMITED (GB) | 2002-10-10 | — | — | US | disclosed |
| CN-1370152-A | 5-cyano-2-aminopyrimidine derivatives | CELLETECH CHIROSCIENCE LTD (GB) | 2002-09-18 | — | — | CN | disclosed |
| EP-1187816-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | Celltech R&D Limited (GB) | 2002-03-20 | — | — | EP | disclosed |
| WO-2000078731-A1 | 5-CYANO-2-AMINOPYRIMIDINE DERIVATIVES | CELLTECH R&D LIMITED (GB) | 2000-12-28 | — | — | WO | disclosed |
| US-5294621-A | Thieno tetrahydropyridines useful as class III antiarrhythmic agents | ORTHO PHARMACEUTICAL CORPORATION (US) | 1994-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118325-A1 | REL INHIBITORS AND METHODS OF USE THEREOF | REL, RCOR3, RBBP4 | CYP19A1 3062/4885NPC1 1943/4885POLB 2063/4885 |
| US-20040180914-A1 | 5-Cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | CYP19A1 350/4885NPC1 3120/4885POLB 832/4885 |
| US-20160257658-A1 | 2-ACYLAMINOTHIAZOLES FOR THE TREATMENT OF CANCER | ALK, ERBB2, ABL1 | CYP19A1 1468/4885NPC1 2964/4885POLB 3321/4885 |
| US-20020147339-A1 | 5-cyano-2-aminopyrimidine derivatives | FLT1, FGFR1, KDR | CYP19A1 371/4885NPC1 3160/4885POLB 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.